Ferri Clodoveo, Feld Jordan J, Bondin Mark, Cacoub Patrice
University of Modena and Reggio Emilia, Modena, Italy.
Toronto Centre for Liver Disease, Toronto General Hospital, University of Toronto, Toronto, ON, Canada.
Antivir Ther. 2018;23(Suppl 2):23-33. doi: 10.3851/IMP3250.
HCV is a carcinogen that is well established as a major risk factor for hepatocellular carcinoma. Evidence that HCV plays a role in the development of extrahepatic malignancies is less robust; however, epidemiological studies have consistently demonstrated an association between HCV infection and B-cell non-Hodgkin lymphoma (NHL). The strongest evidence for a link between HCV and tumourigenesis is the clear association between viral eradication, as indicated by achievement of sustained virological response, and remission of B-cell NHL. All-oral direct-acting antiviral-based therapies are effective in patients with HCV-associated NHL and well tolerated. For this reason, it is important that clinicians assess HCV-infected patients for HCV-associated extrahepatic malignancies so patients can receive timely diagnosis and treatment.
丙型肝炎病毒（HCV）是一种致癌物，已被确认为肝细胞癌的主要危险因素。HCV在肝外恶性肿瘤发生中起作用的证据尚不充分；然而，流行病学研究一直表明HCV感染与B细胞非霍奇金淋巴瘤（NHL）之间存在关联。HCV与肿瘤发生之间联系的最有力证据是，持续病毒学应答的实现所表明的病毒清除与B细胞NHL缓解之间的明确关联。基于全口服直接抗病毒药物的疗法对丙型肝炎病毒相关非霍奇金淋巴瘤患者有效且耐受性良好。因此，临床医生评估丙型肝炎病毒感染患者是否患有丙型肝炎病毒相关肝外恶性肿瘤非常重要，以便患者能够及时得到诊断和治疗。
